

# Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice

NCT07302802

---

**Status** RECRUITING  
**Sponsor** Prof. Dr. Martin Wabitsch  
**Enrollment** 70 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- Treatment with semaglutide as prescribed in routine clinical practice according to summary of product characteristics.
- Informed consent of the patient, their parents, or legally acceptable representative (LAR) of participant and adolescent assent, as age-appropriate.
- Age at time of signing informed consent: e12 to \<21 years.
- BMI e95th percentile as defined on sex- and age-specific BMI growth charts (CDC.gov)
- Body weight of \>60 kg.

... and 1 more (see full listing online)

### Exclusion (15)

- Participation in any interventional clinical trials at the time of enrolment.
- Females of childbearing potential who are not using adequate contraceptive methods (as required by local law or practice)
- Hypersensitivity to the active substance or to any of the excipients listed:
- Disodium phosphate, dihydrate
- Propylene glycol

... and 10 more (see full listing online)

## Locations (7 total)

---

Assistance Publique-Hôpitaux de Paris (AP-HP), Trousseau Hospital Paris, Pediatric Nutrition Department, Paris, France  
Institute for Experimental Pediatric Endocrinology, Charité Universitätsmedizin Berlin, Berlin, Germany  
University Hospital for Children and Adolescents, Center for Pediatric Research, Medical Faculty, University of Leipzig, Leipzig, Germany

... and 4 more locations